Kampanjeplan Eterna Therapeutics Inc.
Avansert tidsplan
Enkel graf
Om selskapet
Eterna Therapeutics Inc., a preclinical-stage, biopharmaceutical company. The company offers Synthetic mRNA, ToRNAdo mRNA Delivery, mRNA Gene Editing, and mRNA Cell Reprogramming. It also develops therapies and medicines using gene-editing proteins and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. The company was formerly known as Brooklyn ImmunoTherapeutics, Inc. and changed its name to Eterna Therapeutics Inc. in October 2022. Eterna Therapeutics Inc. is based in Cambridge, Massachusetts.
Выручка |
0.0198 |
EBITDA |
0.002 |
Число акций ао |
0.00531 млрд |
P/S |
0.3135 |
P/BV |
1.22 |
EV/EBITDA |
4.62 |
Цена ао |
2.26 |
P/E |
3.31 |
ISIN |
US1140821000 |
Сайт |
https://eternatx.com
|
Валюта |
usd |
IPO date |
1992-10-19 |
Sector |
Health Care |
Industry |
Biotechnology |
Валюта отчета |
usd |
Prisendring per dag: |
+3.64% (0.95) |
Prisendring per uke: |
-14.38% (1.15) |
Prisendring per måned: |
-41.39% (1.68) |
Prisendring over 3 måneder: |
-45.6% (1.81) |
Prisendring over seks måneder: |
-54.83% (2.18) |
Prisendring per år: |
-55.85% (2.23) |
Prisendring over 3 år: |
-89.61% (9.48) |
Prisendring over 5 år: |
-59.48% (2.43) |
Prisendring siden begynnelsen av året: |
-25.97% (1.33) |
|
Undervurdering
Navn |
Betydning |
Karakter |
P/S |
146.14 |
1 |
P/BV |
4.45 |
4 |
P/E |
0 |
0 |
EV/EBITDA |
-2.26 |
0 |
Total: |
|
3.25 |
|
Effektivitet
Navn |
Betydning |
Karakter |
ROA, % |
-44.1 |
0 |
ROE, % |
-970.35 |
0 |
Total: |
|
0 |
|
|
Utbytte
Navn |
Betydning |
Karakter |
Div yield, % |
0 |
0 |
DSI |
0 |
0 |
Total: |
|
0.0029 |
|
Plikt
Navn |
Betydning |
Karakter |
Debt/EBITDA |
-0.4598 |
10 |
Total: |
|
10 |
|
Vekstimpuls
Navn |
Betydning |
Karakter |
Lønnsomhet Revenue, % |
-99.68 |
0 |
Lønnsomhet Ebitda, % |
-475.98 |
0 |
Lønnsomhet EPS, % |
472.69 |
10 |
Total: |
|
4 |
|
Veileder |
Stillingstittel |
Betaling |
Fødselsår |
Ms. Sandra M. Gurrola |
Principal Financial & Accounting Officer and Senior VP of Finance |
305.88k |
1967 (57 år) |
Mr. Sanjeev Luther |
CEO, President & Director |
N/A |
1962 (62 år) |
Ms. Dorothy J. Clarke |
General Counsel & Director |
N/A |
1966 (58 år) |
Dr. Robert Hamilton Pierce M.D. |
Chief Scientific Officer |
|
1964 (60 år) |